» Articles » PMID: 35970817

Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus

Abstract

Background: Human cytomegalovirus (HCMV) is the most common infectious complication of organ transplantation and cause of birth defects worldwide. There are limited therapeutic options and no licensed vaccine to prevent HCMV infection or disease. To inform development of HCMV antibody-based interventions, a previous study identified individuals with potent and broad plasma HCMV-neutralizing activity, termed elite neutralizers (ENs), from a cohort of HCMV-seropositive (SP) blood donors. However, the specificities and functions of plasma antibodies associated with EN status remained undefined.

Methods: We sought to determine the plasma antibody specificities, breadth, and Fc-mediated antibody effector functions associated with the most potent HCMV-neutralizing responses in plasma from ENs (n = 25) relative to that from SP donors (n = 19). We measured antibody binding against various HCMV strains and glycoprotein targets and evaluated Fc-mediated effector functions, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).

Results: We demonstrate that ENs have elevated immunoglobulin G binding responses against multiple viral glycoproteins, relative to SP donors. Our study also revealed potent HCMV-specific antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis activity of plasma from ENs.

Conclusions: We conclude that antibody responses against multiple glycoprotein specificities may be needed to achieve potent plasma neutralization and that potently HCMV elite-neutralizing plasma antibodies can also mediate polyfunctional responses.

Citing Articles

Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice.

Watts J, Clinton J, Pollet J, Peng R, Tan J, Ling P Vaccines (Basel). 2025; 12(12.

PMID: 39772089 PMC: 11728668. DOI: 10.3390/vaccines12121429.


Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.

Hu X, Karthigeyan K, Herbek S, Valencia S, Jenks J, Webster H J Infect Dis. 2024; 230(2):455-466.

PMID: 38324766 PMC: 11326847. DOI: 10.1093/infdis/jiad593.


ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission.

Semmes E, Miller I, Rodgers N, Phan C, Hurst J, Walsh K JCI Insight. 2023; 8(13).

PMID: 37427588 PMC: 10371338. DOI: 10.1172/jci.insight.167768.

References
1.
Wang H, Valencia S, Pfeifer S, Jensen J, Kowalik T, Permar S . Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity. Viruses. 2021; 13(6). PMC: 8227702. DOI: 10.3390/v13061106. View

2.
Fouts A, Chan P, Stephan J, Vandlen R, Feierbach B . Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012; 86(13):7444-7. PMC: 3416310. DOI: 10.1128/JVI.00467-12. View

3.
Jenks J, Nelson C, Roark H, Goodwin M, Pass R, Bernstein D . Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans. Sci Transl Med. 2020; 12(568). PMC: 8058742. DOI: 10.1126/scitranslmed.abb3611. View

4.
Bernstein D, Munoz F, Callahan S, Rupp R, Wootton S, Edwards K . Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine. 2015; 34(3):313-9. PMC: 4701617. DOI: 10.1016/j.vaccine.2015.11.056. View

5.
Huang J, Ofek G, Laub L, Louder M, Doria-Rose N, Longo N . Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012; 491(7424):406-12. PMC: 4854285. DOI: 10.1038/nature11544. View